Research Library / Neurocognitive / Dihexa
Neurocognitive researchDihexa (PNB-0408)
PNB-0408 · Angiotensin-IV analog
An experimental peptidomimetic studied for synaptogenic and neuroplastic effects in preclinical models. The listed community example (common low oral schedule) describes 5–10 mg per administration, once daily, via oral; this is not a validated dosing recommendation. No standardized generic reconstitution example is established. For research and education only, not personal medical guidance.
Quick Reference
- Evidence
- Preclinical
- Presentation
- Not standardized
- Clinical context
- See cited product or study
- Diluent
- Not assigned
No generic aqueous preparation is shown: supplier material is described as water-insoluble. Laboratory organic-solvent stocks do not establish a human injection method.
Research schedules
No established clinical dose, route or frequency
Human evidence is absent, limited or not confirmatoryPubMed literature| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Common low oral schedule | 5–10 mg | 5–10 mg/day | Once daily | Morning | Oral | Community-reported |
| Community subcutaneous range | 1–5 mg | 1–5 mg/day | Once daily | Morning | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
No standardized example
No generic aqueous preparation is shown: supplier material is described as water-insoluble. Laboratory organic-solvent stocks do not establish a human injection method.
Supplies & vial yield
Supply total not calculated
No standardized injectable planning basis
No generic aqueous preparation is shown: supplier material is described as water-insoluble. Laboratory organic-solvent stocks do not establish a human injection method.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Dihexa · PNB-0408 · Angiotensin-IV analog
- Evidence / status
- Preclinical. Investigational — not FDA approved
- Clinical route, frequency & duration
Evidence landscape: No established clinical dose, route or frequency
- Community purpose
- Learning, memory, neuroplasticity, and cognitive-performance research.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
A laboratory supplier describes Dihexa as water-insoluble and uses organic-solvent stocks. The former generic water-volume illustration should not be read as a preparation method.
Other vehicles and approaches discussed
DMSO and other laboratory vehicles are not a validated human injectable formulation. No substitute injection recipe is supplied.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Poor aqueous solubility; no generic preparation
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Poor aqueous solubility; no generic preparation
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Proposed HGF/c-Met signaling modulation
An experimental peptidomimetic studied for synaptogenic and neuroplastic effects in preclinical models.
Community-reported purpose
Learning, memory, neuroplasticity, and cognitive-performance research.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Evidence landscape
Protocol: No established clinical dose, route or frequency
Population: Human evidence is absent, limited or not confirmatory
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
There is no established therapeutic human exposure, efficacy or long-term safety profile.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Dihexa?
An experimental peptidomimetic studied for synaptogenic and neuroplastic effects in preclinical models.
Proposed HGF/c-Met signaling modulation
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
A laboratory supplier describes Dihexa as water-insoluble and uses organic-solvent stocks. The former generic water-volume illustration should not be read as a preparation method.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapePubMed literature: Evidence landscape
- Laboratory supplier or secondary reference — product-specificSelleck Dihexa specifications
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.